For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.
That routine just changed.
On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.
This is not a minor update to an existing drug.
It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.
Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.
That means reducing from 365 injections a year down to just 52.
For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.
It represents relief.
How the Drug Actually Works
Understanding why this injection lasts a full week requires a quick look inside the body.
Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.
Awiqli works differently.
Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.
This attachment creates a slow-release reservoir.
Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock.
The drug is delivered using the Awiqli FlexTouch pen, a prefilled device that makes self-injection straightforward and does not require the user to draw insulin from a vial.
It is injected just beneath the skin — what doctors call a subcutaneous injection — and the process closely mirrors what daily insulin users already do, just far less often.
How the Study Was Conducted
Before any drug reaches pharmacy shelves, it must prove itself in people.
For Awiqli, that proof came through the ONWARDS clinical program, one of the most comprehensive trials ever conducted for a new insulin formulation.
The program included five randomized, active-controlled, treat-to-target clinical trials involving approximately 4,000 adults with type 2 diabetes who had previously struggled to control their blood sugar despite medication.
The trials compared once-weekly Awiqli directly against the gold-standard daily basal insulins already in wide use, including insulin glargine U-100 and insulin degludec.
Each trial ran for between 26 and 78 weeks, giving researchers a thorough look at both short-term performance and longer-term patterns.
Participants came from diverse backgrounds, used a range of oral diabetes medications alongside their insulin, and included both insulin-naive individuals (those starting basal insulin for the first time) and those who had already been on daily regimens.
The primary measurement in each trial was HbA1c, a blood marker that reflects average blood sugar levels over the past two to three months and is considered the most reliable indicator of overall diabetes control.
The trials also tracked time in range, a newer metric that measures how many hours per day blood sugar stays within a healthy window of 70 to 180 milligrams per deciliter.
Notably, the FDA-approved label for Awiqli is the first basal insulin label in history to include time-in-range data, which signals a meaningful shift in how regulators are starting to evaluate and communicate glucose management.
Findings From the Study
The results, across all four trials used in the FDA’s final decision, pointed clearly in one direction.
Awiqli matched or outperformed daily insulin across every key measure.
In ONWARDS 1, a 78-week trial with 984 insulin-naive adults, patients on once-weekly Awiqli saw their HbA1c drop by an average of 1.55% compared to 1.35% in those using daily insulin glargine.
In ONWARDS 2, which compared Awiqli to daily insulin degludec, HbA1c fell by 0.90% with the weekly injection versus 0.71% with the daily shot.
ONWARDS 3 and ONWARDS 4 showed similar patterns, with Awiqli consistently achieving stronger or equivalent blood sugar reductions compared to its daily counterparts.
The time-in-range results were equally encouraging.
In a trial involving patients who had never used insulin before, those starting on Awiqli spent 71.9% of the time in a healthy blood sugar range during the final weeks of the trial.
The daily insulin group spent just 66.9% of the time in range during the same period.
That gap may sound small in percentage terms, but for a person with diabetes, those extra hours of stable blood sugar each day can translate to less fatigue, better sleep, and fewer long-term complications including nerve damage, kidney disease, and vision loss.
The safety profile of Awiqli closely resembled that of existing basal insulins.
The most common side effect was hypoglycemia, or low blood sugar, which is expected with any insulin therapy.
Injection site reactions, mild swelling in the feet, and weight gain were also reported, all consistent with what daily insulin users already experience.
The Part Most People Get Wrong About Convenience
Here is where things get more interesting — and where the real story of this approval comes into focus.
Most people assume that the once-weekly format is valuable mainly because it is convenient.
Fewer needles, simpler scheduling, less hassle.
And yes, those things matter.
But the deeper medical insight is this: convenience is not just about comfort. It is about whether people actually take their medication at all.
Research has consistently shown that a staggering number of people on daily insulin simply do not stick to their regimens.
A study published in research supported by the American Diabetes Association found that people with type 2 diabetes using basal insulin missed doses more frequently than their doctors realized, and that doctors consistently underestimated how often their patients were skipping shots.
A separate study involving 415 diabetic patients found that 40.7% reported forgetting at least one insulin dose every week.
The reasons were ordinary and entirely human: being away from home, feeling embarrassed to inject in public, traveling, simply forgetting.
What this means is that the current daily insulin system is not just a minor inconvenience.
For a significant portion of the people who need it most, it is failing them.
And that is what makes the ONWARDS trial’s patient satisfaction data so striking.
In ONWARDS 2, 93.7% of participants using once-weekly Awiqli said they preferred the weekly regimen over their previous daily injections.
They cited fewer injections and greater ease of use as the primary reasons.
Physician satisfaction pointed the same direction, with doctors more likely to recommend the weekly format after witnessing patient responses.
Reducing injections from seven per week to one is not simply about convenience.
It is about building a treatment routine that people will actually follow consistently, and consistency is what determines whether blood sugar stays controlled over years and decades, not just on the day of a clinical trial.
How Awiqli Applies to Real Life
For a newly diagnosed person with type 2 diabetes who is about to start insulin therapy, the psychological hurdle of daily injections is often enormous.
Research consistently shows that injection anxiety and what doctors call psychological insulin resistance cause many patients to delay starting basal insulin for months or even years after their doctor recommends it.
Every delay means more time with uncontrolled blood sugar, which silently damages blood vessels, kidneys, and nerves long before symptoms appear.
A once-weekly option removes much of that friction.
Knowing that one shot will carry you through an entire week makes the commitment feel far less overwhelming.
For someone already on daily insulin who struggles with adherence, the calculus is similar.
Remembering to take a medication seven times a week requires a level of routine discipline that is genuinely hard to maintain, especially across years or decades of treatment.
Remembering once a week is categorically easier.
For people who also take once-weekly GLP-1 medications like semaglutide (Ozempic) or tirzepatide (Mounjaro), Awiqli now opens the door to a fully weekly injectable regimen, meaning all injections could potentially happen on the same day, with the same pen routine.
Doctors at the 2026 American Diabetes Association conference have already started discussing how this fits into a broader shift toward personalized, simplified diabetes management, one that reduces the daily cognitive and physical burden on patients without sacrificing clinical outcomes.
Who Can Use It, and Who Should Wait
It is worth being clear about what this approval does and does not cover.
Awiqli is currently approved only for adults with type 2 diabetes.
The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.
Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2.
Some doctors have also flagged practical considerations for certain patients.
People whose activity levels change significantly from week to week, such as those who exercise heavily on some days and are sedentary on others, may face challenges because the insulin’s effect cannot be easily adjusted mid-week the way a daily dose can.
Endocrinologist Dr. Anne Peters of the University of Southern California has pointed out that highly active patients with variable routines could be harder to manage on a fixed weekly dose.
Those considerations are real, but they apply to a relatively narrow slice of the type 2 diabetes population.
For the majority of adults with type 2 diabetes, particularly those who are newly starting insulin or who struggle with daily adherence, the benefit clearly outweighs the added complexity of a longer-acting formulation.
What Comes Next
Awiqli is not standing alone in this space for long.
Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.
If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.
The broader direction of travel in diabetes care is unmistakable.
Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise.
Awiqli will be available nationally across the United States in the coming months, Novo Nordisk confirmed in its announcement.
The price and insurance coverage landscape is still developing, and access will likely vary depending on health plans and geography, which remains one of the most significant real-world barriers for any new diabetes medication.
A physician who spoke to Medscape Medical News raised this directly, noting that patients who struggle most with adherence are often the same ones who are least likely to gain quick access to an expensive new drug.
That tension between medical innovation and equitable access is not new in diabetes care, and it will need to be addressed by insurers, policymakers, and patient advocates as Awiqli rolls out.
A Small Shot With Large Implications
It is easy to look at a once-weekly injection and see only a scheduling change.
But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.
Diabetes management has always asked a lot of people.
It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.
Anything that reduces that load, without reducing the quality of care, is worth taking seriously.
For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.
That is the real significance of what the FDA approved on March 26, 2026.
Not just a new drug.
A new way of keeping people healthy, one week at a time.
If you or someone you care for is managing type 2 diabetes with insulin, it may be worth asking a doctor whether once-weekly basal insulin could be a better fit for your routine.
References and Further Reading
FDA Approves Novo Nordisk’s Awiqli, the First Once-Weekly Basal Insulin for Type 2 Diabetes
Awiqli Clinical Overview and Patient Guide via WebMD
